Can 3D printing of oral drugs help fight the current COVID-19 pandemic (and similar crisis in the future)?

Wen Kai Hsiao*, Barbara Lorber, Amrit Paudel

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review


The ongoing COVID-19 crisis has highlighted the importance of a robust drug supply chain which can be quickly and flexibly ramped up to produce life-saving drug treatments. 3D printing (3DP) of oral solid dosage forms (OSDF) could be a viable part of the emergency drug production response to support vulnerable patients in rural regions and other isolated locations. In the context of the current pandemic, the suitability of different 3DP technologies will depend on the physicochemical properties, unit dose strength and BCS classification of the repurposed drug compounds currently being trialed for COVID-19. Furthermore, the deployment strategy should focus on simplifying dosage forms and formulations, scaling down the size and complexity of the printing systems and real-time quality assurance via process analytical technologies (PAT).
Original languageEnglish
Pages (from-to)899-902
Number of pages4
JournalExpert Opinion on Drug Delivery
Issue number7
Publication statusPublished - 3 Jun 2020


  • COVID-19; SARS-CoV-2;coronavirus; three-dimensional printing; oral solid dosage forms;epidemic; pandemic; drug supply chain; distributed manufacturing
  • COVID-19
  • distributed manufacturing
  • SARS-CoV-2
  • epidemic
  • three-dimensional printing
  • drug supply chain
  • coronavirus
  • oral solid dosage forms
  • pandemic

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this